Evidence map›Paper›PMID 27032774›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2016

Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.

Katja Kollewe, Claus M Escher, Dirk U Wulff, Davood Fathi, Lejla Paracka, Bahram Mohammadi, Matthias Karst, Dirk Dressler

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05646160 (Effects of Myofascial Trigger Points Therapy in Migraine.), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05646160 naunknown statusnot on this mapstarted 2018, after this paper: background citation

Effects of Myofascial Trigger Points Therapy in Migraine.

TypeinterventionalSponsorJózef Piłsudski University of Physical EducationRan2018 to 2023Enrolled100ConditionsMigraine, Pain, Shoulder, Trapezius Muscle Strain Left, Trapezius Muscle Strain RightArmsIschemic Compression of Myofascial Trigger Points (IC-MTRPs)
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Review
  9. Observational
  10. The Use of Botulinum Toxin for Treatment of Depression.Handbook of experimental pharmacology · 2021
    Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katja KolleweDepartment of Neurology, Movement Disorder Section, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. kollewe.katja@mh-hannover.de.
Claus M EscherDepartment of Neurology, Movement Disorder Section, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Dirk U WulffMax Planck Institute for Human Development, Berlin, Germany.
Davood FathiDepartment of Neurology, Movement Disorder Section, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Lejla ParackaDepartment of Neurology, Movement Disorder Section, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Bahram MohammadiInternational Neuroscience Institute, Hannover, Germany.
Matthias KarstDepartment of Anaesthesiology, Pain Clinic, Hannover Medical School, Hannover, Germany.
Dirk DresslerDepartment of Neurology, Movement Disorder Section, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulinum toxin was shown to be effective in treatment of chronic migraine. We wanted to explore its efficacy and tolerability in chronic application under real-life conditions. For this, 27 consecutive patients (age 45.6 ± 10.8 years, 25 females, 2 males) received altogether 176 injection series (IS) with 189.7 ± 45.8MU onabotulinumtoxinA (Botox(®)) according to the PREEMPT scheme. During the study period altogether 6.5 ± 2.9 (min 4, max 13) IS were applied per patient (total treatment time of 73.1 ± 36.9 weeks). 96 % of the patients reported benefit. Monthly headache days were reduced from 18.9 ± 3.9 to 8.7 ± 4.5 (p < 0.001, -53.7 %), migraine days from 16.8 ± 4.9 to 7.4 ± 4.6 (p < 0.001, -55.1 %), autonomic days from 8.6 ± 7.5 to 2.7 ± 4.2 (p < 0.001, -71.9 %) and medication days from 14.2 ± 4.6 to 8.3 ± 4.2 (p < 0.001, -71.1 %). Health-related quality of life improved by 0.6-1.5 standard deviations (SD) (Short Form Health Survey), migraine-related quality of life by 1.4-2.0 SD (Migraine-Specific Quality of Life Questionnaire) and by 1.9 SD (Headache Impact Test), depression by 1.1 SD (Beck Depression Inventory). Subjective global clinical improvement was 2.6 ± 0.6 (Global Clinical Improvement Scale). All improvements were stable throughout the entire study period. Adverse effects were infrequent, mild and transient. Botulinum toxin provides highly effective and safe long-term treatment of chronic migraine.

Indexed as

Treatment OutcomeAcetylcholine Release InhibitorsAdultBotulinum Toxins, Type AChronic DiseaseFemaleHumansLongitudinal StudiesMaleMiddle AgedMigraine DisordersQuality of LifeRetrospective StudiesSeverity of Illness IndexSurveys and QuestionnairesTime FactorsAcetylcholine Release InhibitorsBotulinum Toxins, Type ABotox®Botulinum toxinChronic migraineLong-term treatmentOnabotulinumtoxinAReal-life setting

Identifiers

PMID27032774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.